GE HealthCare Technologies Inc. (GEHC) · Oct 28, 2026 · Earnings

GE HealthCare earnings beat, EPS guidance raised on broad growth

Beat — Adjusted EPS $1.34 vs ~$1.20 consensus

GE HealthCare earnings beat expectations across revenue and adjusted EPS, while management raised 2026 EPS and margin guidance.

GE HealthCare is a diversified medical-technology and diagnostics company pushing its D3 strategy: connected devices, pharmaceuticals, AI, cloud, and software across the care journey. Its recent Intelerad acquisition is accelerating the cloud-first enterprise-imaging piece of that strategy.

The quarter materially exceeded the standing bar. Published estimates clustered around roughly $1.20–$1.23 of adjusted EPS and about $5.46 billion of revenue; GE HealthCare delivered $1.34 and $5.513 billion, respectively.

MetricQ3 2026Q3 2025 / prior guideChange or comparison
Total revenue$5.513B$5.143B+7.2% YoY (Income Statement)
Organic revenue$5.462B$5.143B+6.2% YoY (Organic Revenue)
Adjusted EPS$1.34$1.07+$0.27 YoY (Adjusted EPS)
Adjusted EBIT margin16.6%14.8%+180 bps YoY (Adjusted EBIT)
Free cash flow$793M$483M+64.2% YoY (Free Cash Flow)
2026 organic revenue growth guide~4.0%3.0%–4.0%Raised to approximately 4.0% (2026 Guidance)
2026 adjusted EPS guide$4.95–$5.05$4.80–$5.00Raised (2026 Guidance)
2026 adjusted EBIT margin guide15.5%–15.7%15.4%–15.7%Range lifted at the low end (2026 Guidance)
2026 free cash flow guide$1.6B+~$1.6BRaised modestly (2026 Guidance)

Growth was broad rather than dependent on one division. Advanced Imaging Solutions grew organic revenue 4.5% with a 130-basis-point margin expansion, Pharmaceutical Diagnostics grew 13.8% organically, and Patient Care Solutions rebounded to 8.8% organic growth with a 480-basis-point margin improvement (Segment Results). That breadth makes the guidance increase more credible than a raise driven only by a one-time tax or acquisition benefit.

The quality of earnings improved alongside sales. Adjusted EBIT rose 19.9% to $913 million and adjusted EBIT margin reached 16.6%, helped by volume, pricing, cost productivity, and favorable tariff effects. Free cash flow also accelerated to $793 million in the quarter and $973 million year to date (Adjusted EBIT; Free Cash Flow). The filing’s tariff refund benefit is not immaterial, but the segment-level margin gains and operating cash flow indicate the quarter was not just a tax-driven beat.

The outlook move is the clearest new information. Management raised full-year organic growth toward 4.0%, lifted the EPS range to $4.95–$5.05, and raised the low end of its margin range. 〔0〕 The direction of improvement was partly anticipated by the prior guidance range; the size and breadth of the upgrade are the surprise.

Secondary developments add execution complexity but do not overturn the quarter. The company reiterated an already announced $945 million cash acquisition of SOFIE Biosciences, expected to close in the first half of 2027. Year-to-date purchases of businesses reached $2.293 billion, while September cash stood at $2.854 billion and long-term borrowings at $9.970 billion (Cash Flow Statement; Balance Sheet). Patient Care Solutions also faces a leadership transition, with President and CEO Jeannette Bankes leaving for another public-company CEO role and Neal Sandy taking over on November 16, 2026. 〔1〕

Bottom line: This is a genuine operating beat, not merely favorable framing: revenue, margins, cash flow, and all three core segments improved, prompting a broader 2026 guidance increase. The acquisition and PCS leadership change matter, but they are secondary to a quarter that advances the company’s growth-and-margin story.

What to watch next

SOFIE Biosciences closing, first half of 2027

Original filing on SEC EDGAR

More GE HealthCare Technologies Inc. news

GE HealthCare earnings beat, EPS guidance raised on broad growth | GEHC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.